SEC Form 4 · accession 0001628280-26-053754
Arcutis Biotherapeutics, Inc. · ARQT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Masaru Matsuda
Officer — See Remarks
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 9:42 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001787306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 3, 2026 | S | 1,230 | $26.1168 | D | 126,171 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
- F2The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3Includes 712 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.
Remarks
Reporting Person's title: EVP, Chief Legal Officer